Table of contents
Volume 89, Issue 10
Published online 11 November 2003 (1817-2017)
Clinical |
Molecular and Cellular Pathology |
Genetics and Genomics |
Experimental Therapeutics |
Letter to the Editor
Minireviews
Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development FREE
C V Hojilla, F F Mohammed and R Khokha
Br J Cancer 89: 1817-1821; doi:10.1038/sj.bjc.6601327
Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity FREE
J Neuzil
Br J Cancer 89: 1822-1826; doi:10.1038/sj.bjc.6601360
Clinical
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer FREE
C Gridelli, P Maione, V Castaldo and A Rossi
Br J Cancer 89: 1827-1829; doi:10.1038/sj.bjc.6601387
Extended duration of the detectable stage by adding HPV test in cervical cancer screening FREE
M E van den Akker-van Marie, M van Ballegooijen, L Rozendaal, C J L M Meijer and J D F Habbema
Br J Cancer 89: 1830-1833; doi:10.1038/sj.bjc.6601355
Experiences of men with breast cancer: an exploratory focus group study FREE
B G Williams, R Iredale, K Brain, E France, P Barrett-Lee and J Gray
Br J Cancer 89: 1834-1836; doi:10.1038/sj.bjc.6601305
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer FREE
D A Cameron, C Massie, G Kerr and R C F Leonard
Br J Cancer 89: 1837-1842; doi:10.1038/sj.bjc.6601366
A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer FREE
P A Vasey, L McMahon, J Paul, N Reed and S B Kaye
Br J Cancer 89: 1843-1848; doi:10.1038/sj.bjc.6601381
Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours – a retrospective long-term follow-up study FREE
J Gaffan, L Holden, E S Newlands, D Short, S Fuller, R H J Begent, G J S Rustin and M J Seckl
Br J Cancer 89: 1849-1854; doi:10.1038/sj.bjc.6601383
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia FREE
S G O'Brien, P Meinhardt, E Bond, J Beck, B Peng, C Dutreix, G Mehring, S Milosavljev, C Huber, R Capdeville and T Fischer
Br J Cancer 89: 1855-1859; doi:10.1038/sj.bjc.6601152
A phase II irinotecan–cisplatin combination in advanced pancreatic cancer FREE
C Markham, D D Stocken and A B Hassan on behalf of the Pancreatic Trials Team
Br J Cancer 89: 1860-1864; doi:10.1038/sj.bjc.6601377
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma FREE
Z Guan, Y Wang, S Maoleekoonpairoj, Z Chen, W S Kim, V Ratanatharathorn, W H H Reece, T W Kim and M Lehnert
Br J Cancer 89: 1865-1869; doi:10.1038/sj.bjc.6601369
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients FREE
C Garufi, E Bria, B Vanni, A M R Zappalà, I Sperduti and E Terzoli
Br J Cancer 89: 1870-1875; doi:10.1038/sj.bjc.6601382
Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus Interleukin-2 FREE
Y Yamaguchi, E Miyahara, A Ohshita, Y Kawabuchi, K Ohta, K Shimizu, K Minami, J Hihara, A Sawamura and T Toge
Br J Cancer 89: 1876-1884; doi:10.1038/sj.bjc.6601379
Evaluation of various cytological examinations by bronchoscopy in the diagnosis of peripheral lung cancer FREE
M Kawaraya, K Gemba, H Ueoka, K Nishii, K Kiura, T Kodani, M Tabata, T Shibayama, T Kitajima and M Tanimoto
Br J Cancer 89: 1885-1888; doi:10.1038/sj.bjc.6601368
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours FREE
D Checkley, J J Tessier, J Kendrew, J C Waterton and S R Wedge
Br J Cancer 89: 1889-1895; doi:10.1038/sj.bjc.6601386
Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing FREE
Y Iwadate, S Fujimoto, H Namba and A Yamaura
Br J Cancer 89: 1896-1900; doi:10.1038/sj.bjc.6601376
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma FREE
S J Strauss, M Marples, M P Napier, T Meyer, J Boxall and G J S Rustin
Br J Cancer 89: 1901-1905; doi:10.1038/sj.bjc.6601414
Molecular and Cellular Pathology
The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer FREE
E J Bromwich, P A McArdle, K Canna, D C McMillan, A-M McNicol, M Brown and M Aitchison
Br J Cancer 89: 1906-1908; doi:10.1038/sj.bjc.6601400
Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma FREE
L Campbell, M Gumbleton and D F R Griffiths
Br J Cancer 89: 1909-1913; doi:10.1038/sj.bjc.6601359
Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development FREE
W Zuidervaart, P A van der Velden, M H Hurks, F A van Nieuwpoort, C J J Out-Luiting, A D Singh, R R Frants, M J Jager and N A Gruis
Br J Cancer 89: 1914-1919; doi:10.1038/sj.bjc.6601374
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence FREE
K Jirström, A Ringberg, M Fernö, L Anagnostaki and G Landberg
Br J Cancer 89: 1920-1926; doi:10.1038/sj.bjc.6601398
Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer FREE
M K Oehler, D C Fischer, M Orlowska-Volk, F Herrle, D G Kieback, M C P Rees and R Bicknell
Br J Cancer 89: 1927-1933; doi:10.1038/sj.bjc.6601397
MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status FREE
H M Müller, H Fiegl, G Goebel, M M Hubalek, A Widschwendter, E Müller-Holzner, C Marth and M Widschwendter
Br J Cancer 89: 1934-1939; doi:10.1038/sj.bjc.6601392
Differential expression profiling of head and neck squamous cell carcinoma (HNSCC) FREE
F Lemaire, R Millon, J Young, A Cromer, C Wasylyk, I Schultz, D Muller, P Marchal, C Zhao, D Melle, L Bracco, J Abecassis and B Wasylyk
Br J Cancer 89: 1940-1949; doi:10.1038/sj.bjc.6601373
Defects in death-inducing signalling complex formation prevent JNK activation and Fas-mediated apoptosis in DU 145 prostate carcinoma cells FREE
J F Curtin and T G Cotter
Br J Cancer 89: 1950-1957; doi:10.1038/sj.bjc.6601393
Genetics and Genomics
BRAF mutations in non-Hodgkin's lymphoma FREE
J W Lee, N J Yoo, Y H Soung, H S Kim, W S Park, S Y Kim, J H Lee, J Y Park, Y G Cho, C J Kim, Y H Ko, S H Kim, S W Nam, J Y Lee and S H Lee
Br J Cancer 89: 1958-1960; doi:10.1038/sj.bjc.6601371
Role of MC1R variants in uveal melanoma FREE
N Hearle, J Humphreys, B E Damato, R Wort, R Talaban, J Wixey, H Green, D F Easton and R S Houlston
Br J Cancer 89: 1961-1965; doi:10.1038/sj.bjc.6601358
CHEK2 variants associate with hereditary prostate cancer FREE
E H Seppälä, T Ikonen, N Mononen, V Autio, A Rökman, M P Matikainen, T L J Tammela and J Schleutker
Br J Cancer 89: 1966-1970; doi:10.1038/sj.bjc.6601425
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity FREE
R W Robey, Y Honjo, K Morisaki, T A Nadjem, S Runge, M Risbood, M S Poruchynsky and S E Bates
Br J Cancer 89: 1971-1978; doi:10.1038/sj.bjc.6601370
Experimental Therapeutics
Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity FREE
C B Seymour, C Mothersill, R Mooney, M Moriarty and K F Tipton
Br J Cancer 89: 1979-1986; doi:10.1038/sj.bjc.6601361
Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer FREE
D Azria, C Larbouret, V Garambois, A Kramar, P Martineau, B Robert, N Aillères, M Ychou, J B Dubois and A Pèlegrin
Br J Cancer 89: 1987-1994; doi:10.1038/sj.bjc.6601362
Study of in vitro and in vivo effects of 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a novel cytostatic and differentiation inducing agent, on human colon cancer cells FREE
J J Wang, Y F Chang, Y T Chern and C W Chi
Br J Cancer 89: 1995-2003; doi:10.1038/sj.bjc.6601337
Anti-inflammatory and anti-invasive effects of 
-melanocyte-stimulating hormone in human melanoma cells FREE
P Eves, J Haycock, C Layton, M Wagner, H Kemp, M Szabo, R Morandini, G Ghanem, J C García-Borrón, C Jiménez-Cervantes and S Mac Neil
Br J Cancer 89: 2004-2015; doi:10.1038/sj.bjc.6601349
Letter to the Editor
Traditional behavioural practices, the exchange of saliva and HHV-8 transmission in sub-Saharan African populations FREE
J M Wojcicki
Br J Cancer 89: 2016-2017; doi:10.1038/sj.bjc.6601390
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
